Trends in linezolid susceptibility patterns in 2002: Report from the worldwide Zyvox Annual Appraisal of Potency and Spectrum Program

Linezolid-resistant methicillin-resistant Staphylococcus aureus isolated after long-term, repeated use of linezolid

“…Since then, several cases of LZD-resistant MRSA, although uncommon, have been reported elsewhere in the world. [5][6][7] Moreover, some reports regarding LZD-resistant VCM-resistant Enterococci (LRVRE) have also been published elsewhere in the world. 10 A few cases of infection caused by LRVRE have also been reported in Japan (not published in the literature).…”

“…4 Reports from other countries on LZD-resistant MRSA also note that such factors as long-term use and low-dose use of LZD are risk factors for resistance. 5,7 A long duration of treatment, low dose, and repeated use of LZD should be recognized as important factors to be avoided when using this drug. In addition, when it is expected that long-term therapy with LZD may be required to completely cure an infection, one possible option might be to consider changing the LZD-based treatment temporarily to a combination treatment with another anti-MRSA agent and rifampicin or minocycline or sulfamethoxazole and trimethoprim (although these agents are not covered by the Japanese national health insurance) to prevent the increasing occurrence of LZD-resistant MRSA.…”

“…While several clinical cases of LZD-resistant MRSA infections [4][5][6][7] have been reported elsewhere in the world, no clinical cases of the disease have been documented in Japan. We report here our experience with a case of LZDresistant MRSA isolated after the long-term, repeated use of LZD.…”

Bacteriophage therapy: a revitalized therapy against bacterial infectious diseases

“…63 More than 50% of clinical S. aureus isolates in Japan today carry multidrug resistance and are generally referred to as methicillin-resistant S. aureus (MRSA). 64 [69][70][71] We therefore examined the possibility of phage therapy for S. aureus infectious disease.…”

Central Venous Catheter Colonization by Linezolid-Resistant, Vancomycin-Susceptible Enterococcus faecalis

“…Linezolid (an oxazolidinone) and quinupristin-dalfopristin (a streptogramin) are newer antibiotics for treating infections due to gram-positive resistant pathogens (6). Enterococcal isolates resistant to linezolid or quinupristin-dalfopristin have been described (10), and there are two reports of E. faecium being resistant to both of these agents (1,2). However, the enterococcal isolates resistant to both linezolid and quinupristin-dalfopristin previously reported were also resistant to vancomycin (1,2).…”